Mid-Day Market Update: Crude Oil Rises Over 1%; Orphazyme Shares Plunge
Midway through trading Friday, the Dow traded down 1.13% to 33,440.28 while the NASDAQ fell 0.74% to 14,056.31. The S&P also fell, dropping 0.92% to 4,183.07.
32 Stocks Moving In Friday’s Mid-Day Session
Gainers
CAI International, Inc. (NYSE: CAI) shares jumped 46.4% to $55.86 after the company agreed to a $1.1 billion takeover by Mitsubishi HC Capital Inc.
Mid-Morning Market Update: Markets Open Lower; Adobe Reports Upbeat Q2 Earnings
Following the market opening Friday, the Dow traded down 1.25% to 33,401.59 while the NASDAQ fell 0.54% to 14,085.56. The S&P also fell, dropping 0.86% to 4,185.44.
ORPH Stock Price Falls Over 40%: Why It Happened
Orphazyme A S ADR (NASDAQ: ORPH) shares are trading lower by 42% at $8.41 Friday morning after the company announced it received a Complete Response Letter from the FDA for its treatment for Niemann-Pick Disease Type C and also cut its FY2021 outlook.
Benzinga Pro’s Top 20 Searched Tickers In Benzinga Pro For Morning Of Friday, Jun. 18, 2021
Orphazyme (ORPH)
AMC Entertainment (AMC)
UTime (UTME)
Midatech Pharma (MTP)
Cellect Biotechnology (APOP)
KULR Technology Group (KULR)
Clearside Biomedical (CLSD)
Advanced Micro Devices (AMD)
CureVac
Benzinga Pro’s Top 5 Stocks To Watch For Friday, Jun. 18, 2021: ORPH, VXRT, STLD, HOFV, TAL
Today's 5 Stock Ideas
Orphazyme (ORPH) - Shares of Thursday's most-watched stock were down 53% Friday morning following news it received a Complete Response Letter from the FDA. A CRL indicates the FDA
The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira’s CEO Placed On Temporary Leave, 5 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 17)
28 Stocks Moving in Friday’s Pre-Market Session
Gainers
CAI International, Inc. (NYSE: CAI) rose 45.1% to $55.35 in pre-market trading after the company agreed to a $1.1 billion takeover by Mitsubishi HC Capital Inc.
Orphazyme Wild Party At Risk As FDA Rejects Its Rare Neurodegenerative Disease Drug
Orphazyme A/S (NASDAQ: ORPH) shares, which have been extremely volatile of late, could come under pressure Friday